Advance Tests, a leader in advanced diagnostics, is bringing a transformative solution to Alzheimer’s diagnosis in the UK with the exclusive launch of LucentAD Complete. Developed by Lucent Diagnostics, a brand of Quanterix Corporation, this innovative blood test combines multiple biomarkers, including p-Tau 217, to deliver highly accurate risk classification for amyloid pathology linked to Alzheimer’s Disease. Starting from 2 December 2024, the test will be accessible to UK patients and healthcare providers, offering a non-invasive and cost-effective alternative to traditional diagnostic methods. What Makes LucentAD Complete Unique? Early Booking Availability Patients and healthcare providers in the UK can now…